Profile data is unavailable for this security.
About the company
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-26.14m
- Incorporated2009
- Employees26.00
- LocationGenprex Inc1601 Trinity StreetBldg. B, Suite 3.322AUSTIN 78712United StatesUSA
- Phone+1 (512) 537-7997
- Fax+1 (302) 655-5049
- Websitehttps://www.genprex.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Capstone Therapeutics Corp | 0.00 | -358.00k | 512.23k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
International Stem Cell Corp | 8.32m | -529.00k | 560.31k | 29.00 | -- | -- | -- | 0.0673 | -0.0661 | -0.0661 | 1.04 | 0.0355 | 1.46 | 2.54 | 11.31 | 286,965.50 | -12.02 | -29.22 | -84.86 | -73.82 | 58.62 | 59.49 | -8.22 | -21.01 | 0.4785 | -3.94 | 0.9254 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
Yield10 Bioscience Inc | 750.00k | -12.70m | 595.81k | 29.00 | -- | -- | -- | 0.7944 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
Genprex Inc | 0.00 | -26.14m | 882.69k | 26.00 | -- | 0.2006 | -- | -- | -16.04 | -16.04 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -232.21 | -92.06 | -318.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
Regen BioPharma Inc | 236.57k | -882.60k | 985.07k | 1.00 | -- | -- | -- | 4.16 | -0.2157 | -0.2157 | 0.0594 | -1.18 | 1.04 | -- | 3.82 | 236,570.00 | -407.33 | -104.36 | -- | -- | -- | -- | -392.01 | -275.00 | -- | -1.36 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
LadRx Corp | 0.00 | -2.77m | 990.18k | 2.00 | -- | -- | -- | -- | -5.59 | -5.59 | 0.00 | -1.89 | 0.00 | -- | -- | 0.00 | -113.62 | -58.97 | -653.73 | -78.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 106.96 | -- | -- | -- |
Entero Therapeutics Inc | 0.00 | -6.44m | 1.04m | 15.00 | -- | 0.0526 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
Herborium Group, Inc. | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
Trevena Inc | 443.00k | -37.03m | 1.25m | 23.00 | -- | -- | -- | 2.81 | -56.17 | -56.17 | 0.6391 | -22.23 | 0.0143 | -- | -- | 19,260.87 | -119.82 | -55.93 | -152.94 | -66.35 | -271.56 | -- | -8,358.24 | -3,134.41 | -- | -20.12 | 2.51 | -- | 847.61 | -11.43 | 24.93 | -- | -24.67 | -- |
PaxMedica Inc | 0.00 | -17.66m | 1.25m | 6.00 | -- | -- | -- | -- | -7.54 | -7.54 | 0.00 | -0.2324 | 0.00 | -- | -- | 0.00 | -594.25 | -755.77 | -2,502.49 | -- | -- | -- | -- | -- | -- | -11,785.74 | -- | -- | -- | -- | -23.56 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Armistice Capital LLCas of 31 Mar 2024 | 97.87k | 4.66% |
Geode Capital Management LLCas of 30 Jun 2024 | 16.50k | 0.79% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 14.98k | 0.71% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 11.39k | 0.54% |
Tower Research Capital LLCas of 31 Mar 2024 | 2.77k | 0.13% |
Brown Brothers Harriman & Co. (Investment Management)as of 30 Jun 2024 | 2.50k | 0.12% |
Group One Trading LPas of 31 Mar 2024 | 828.00 | 0.04% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 791.00 | 0.04% |
Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 704.00 | 0.03% |
UBS Financial Services, Inc.as of 31 Mar 2024 | 591.00 | 0.03% |